The price you pay for Rytary may depend on factors such as your dosage, whether you have health insurance, and the pharmacy you use. Financial assistance may be available to help you with the cost ...

Impax Laboratories and Dr. Reddy’s have settled their patent infringement dispute over Rytary, a medication used to treat Parkinson’s disease. Walgreens’ three core segments—U.S. pharmacy ...

JP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue forecast, with peak sales over $300 million.

Q4 2024 Management View Chirag Patel, Co-CEO, highlighted Amneal's "stellar financial performance" in 2024, citing double-digit revenue and adjusted EBITDA growth, reduction of net leverage below four ...

The drug is capturing market share faster than expected, making up about 15% of Rytary’s volume. Schott anticipates strong growth throughout the year as Amneal expands insurance coverage.

He added that Amneal expects continued top- and bottom-line growth in 2025, despite the loss of exclusivity for Rytary. Amneal projects 2025 total revenue of $3.0B-$3.1B, driven by double-digit ...